The easy-to-use COVID-19 PCR saliva test allows U.S. and Canadian travelers to collect their own samples from their homes, offices or hotel rooms
Toronto, Ontario and Richmond, Virginia / ACCESSWIRE / November 18, 2021 / StageZero Life Sciences, Ltd. (TSX: SZLS) (OTC: SZLSF) ("StageZero" or "Company" "), a vertically integrated healthcare company dedicated to improving early detection and management of cancer and other chronic diseases through leading molecular diagnostics and clinical interventions, today announced the launch of BORDERPASS™ COVID-19 RT-PCR saliva testing. The BORDERPASS™ kit allows travelers to collect their COVID PCR saliva samples from the comfort of their home, office or hotel room. StageZero will begin providing COVID-19 testing in April 2020.
With the relaxation of travel restrictions between the United States and Canada, international travel is rapidly heating up. According to today’s expected announcement, Canada will continue to require all non-Canadians and Canadians who have been abroad for more than 72 hours to provide a negative COVID PCR test before entering the country.
The BORDERPASS™ RT-PCR saliva test makes it easy and convenient for travelers to take the COVID PCR test without having to scramble to find a PCR clinic on the go. BORDERPASS™ PCR test results are accepted in Canada, the United States, and most international borders.
One-way and two-way BORDERPASS™ test kits are available for passengers departing from the United States or Canada. Saliva samples were collected by travelers themselves using Ichor Blood Services' video conferencing function under the video supervision of healthcare professionals. Passengers then only need to ask FedEx to take their samples and transport them to the StageZero laboratory in the provided packaging. The laboratory will send the test results via email within 24 hours after receiving the samples.
“For Canadians and Americans who wish to reunite with their loved ones, restart business trips and explore new destinations, the reopening of borders is a joyous moment. However, COVID-19 still poses a major threat to our health and well-being, and James Howard-Tripp, Chairman and CEO of StageZero Life Sciences, said: "It is important for travelers to take precautions to ensure the safety of their travel and help control the spread of the virus. "Through BORDERPASS™, we provide travelers with convenience without having to find a clinic, and knowing that their PCR test will be accepted at the border, gives them peace of mind. "
The BORDERPASS™ personal test kit can be purchased online or in stores across Canada. Enterprise prices apply to enterprises. For more information, please visit www.stagezeroborderpass.com.
About StageZero Life Science Co., Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telemedicine program that provides clinical interventions to help patients reduce late-stage development Risk stage disease (AVRT™).
The company's next-generation test, Aristotle®, is the first ever mRNA multi-cancer detection group, which can simultaneously screen multiple cancers from a single blood sample, with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular characteristics of multiple cancer types and is based on the company's patented technology platform Sentinel Principle. This basic technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
Aristotle® and other cancer diagnoses (ColonSentry®, BreastSentry™ and Prostate Health Index) are processed in the company’s clinical laboratory, StageZero Life Sciences, Inc., which is CAP accredited and CLIA accredited in Richmond High Complexity Reference Laboratory, Virginia. In addition, the company also uses its expertise in polymerase chain reaction (PCR) testing to provide COVID-19 PCR tests (swabs and saliva) and antibody tests (blood analysis).
The trading code of StageZero Life Sciences on the Toronto Stock Exchange is SZLS, and the trading code on OTCQB is SZLSF.
This press release contains forward-looking statements identified as "expects", "will" and similar expressions that reflect the company's current expectations of future events. Forward-looking statements involve risks and uncertainties, and may cause the company's actual events to differ materially from the events predicted here. Investors should consult the company's ongoing quarterly documents and annual reports for more information about the risks and uncertainties associated with these forward-looking statements. Readers are cautioned not to rely on these forward-looking statements. Except as required by law, the company assumes no obligation to update these forward-looking statements.
For more information, please contact:
Investor Relations Rebecca Greco 1-855-420-7140 ext. Chapter 1838
Media contact Kristin Villiotte SHIFT newsletter kvilliotte@shiftcomm.com
Source: StageZero Life Sciences Ltd.
View the source version on accesswire.com: https://www.accesswire.com/673759/StageZero-Life-Sciences-Introduces-BORDERPASSTM-COVID-19-PCR-Testing-for-Travelers
© 1985-2021 BioSpace.com. all rights reserved. Supported by Madgex work board software